- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03626857
MiACLR: Michigan Initiative for Anterior Cruciate Ligament Rehabilitation (MiACLR)
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
Ann Arbor, Michigan, United States, 48109
- MedSport
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Acute, complete ACL rupture
- ACL reconstruction with autograft
- Scheduled to undergo ACLR at U of Michigan
- Willingness to participate in testing and follow-up as outlined
Exclusion Criteria:
- Previous surgery to either knee
- Bony fracture accompanying ACL injury
- Patients who experienced a knee dislocation
- Female participants who are pregnant or planning pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: NMES+ECC
Neuromuscular electrical stimulation (NMES) and Eccentric Exercise (ECC).
Patients randomized to the NMES+ECC group will first receive NMES for 2x/week for 8 weeks, beginning at the first post-operative visit.
Beginning at 9 weeks after anterior cruciate ligament reconstruction (ACLR) patients will begin to receive eccentric exercise 2x/week for an additional 8 weeks.
For NMES, patients will have electrical stimulation delivered to their quadriceps.
Fifteen isometric actions lasting 10 seconds each will be elicited during each session.
For eccentric exercise, patients will train for 4 sets of 10 repetitions.
This group will also receive standard of care ACL rehabilitation alongside the study interventions.
|
The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period.
Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of at least 40& of the contralateral MVIC.
Other Names:
4 sets of 10 repetitions of an eccentric leg press exercise performed at 70-90% of the 1 repetition maximum
|
|
Placebo Comparator: NMES placebo + ECC placebo
Neuromuscular electrical stimulation (NMES) low intensity/placebo + Eccentric Exercise (ECC) low intensity/placebo arm. Patients randomized to the NMES low intesntiy/placebo + ECC low intensity/placebo group will first receive NMES placebo/low-intensity treatment for 2x/week for 8 weeks, beginning at the first post-operative physical therapy visit. Beginning at 9 weeks after anterior cruciate ligament reconstruction (ACLR) patients will begin to receive an eccentric exercise low-intensity/placebo 2x/week for 8 weeks. For the NMES low intensity/placebo, patients will have it delivered to their quadriceps 2x/week for 8 weeks beginning at the first post-operative visit. Fifteen isometric actions lasting 10 seconds each will be elicited during each session. For the eccentric exercise low-intensity/placebo, patients will begin to receive eccentric exercise two times per week for 8 weeks. Patients will train for 4 sets of 10 repetitions. |
The electrical stimulator will deliver a 2500 Hz alternating current, modulated at 75 bursts/s, with a ramp-up time of 2-seconds, followed by a 50-second rest period.
Stimulus intensity set to generate a maximum voluntary isometric contraction (MVIC) of 10-20% of the contralateral MVIC.
4 sets of 10 repetitions of an eccentric leg press exercise performed at 10-20% of the 1 repetition maximum
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Immediately Post NMES+ECC Intervention Isokinetic Quadriceps Strength Index
Time Frame: Post-NMES+ECC intervention (approximately 16 weeks post-ACL reconstruction)
|
Bilateral concentric isokinetic muscle strength at 60 degrees per second.
Limb symmetry index is calculated as (ACL strength/Non-ACL strength)*100
|
Post-NMES+ECC intervention (approximately 16 weeks post-ACL reconstruction)
|
|
9 Months Isokinetic Quadriceps Strength Limb Symmetry Index
Time Frame: 9 months (9 months post-ACL reconstruction)
|
Bilateral concentric isokinetic muscle strength at 60 degrees per second.
Limb symmetry index is calculated as (ACL strength/Non-ACL strength)*100
|
9 months (9 months post-ACL reconstruction)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Knee Flexion Angle at 9 Months
Time Frame: 9 months post-ACL reconstruction
|
Peak knee flexion angle of the ACL leg recorded during a single-legged hop (units: degrees)
|
9 months post-ACL reconstruction
|
|
Knee Flexion Moment at 9 Months
Time Frame: 9 months post-ACL reconstruction
|
Peak knee flexion moment recorded during a single-legged hop (units: Nm/kg*m)
|
9 months post-ACL reconstruction
|
|
Knee Flexion Angle at 18 Months
Time Frame: 18 months post-ACL reconstruction
|
Peak knee flexion angle recorded during a single-legged hop (units: degrees)
|
18 months post-ACL reconstruction
|
|
Knee Flexion Moment at 18 Months
Time Frame: 18 months post-ACL reconstruction
|
Peak knee flexion moment recorded during a single-legged hop (units: Nm/kg*m)
|
18 months post-ACL reconstruction
|
|
T1 Rho Relaxation Time Symmetry Score for Femoral Knee Joint Cartilage
Time Frame: 18 months post-ACL reconstruction
|
[T1rho value at the weight bearing region of medial femur from MRI for ACL knee (msec)/T1rho value at the weight bearing region of medial femur for NonACL knee (msec)] x 100
|
18 months post-ACL reconstruction
|
|
T2 Relaxation Time Symmetry Score for Femoral Knee Joint Cartilage
Time Frame: 18 months post-ACL reconstruction
|
[T2 value from MRI at the central weight bearing region of femur for the ACL knee (msec)/T2 value from MRI at the central weight bearing region of femur for the NonACL knee (msec)] x 100
|
18 months post-ACL reconstruction
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HUM00144992
- 1R01HD093626-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.